This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / LOTTE Biologics, Ottimo Pharma...
Business partnership expansion

LOTTE Biologics, Ottimo Pharma expand antibody agreement

Analysis based on 6 articles · First reported May 18, 2026 · Last updated May 18, 2026

Sentiment
60
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The expanded collaboration between Lotte Biologics and Ottimo Pharma is expected to positively impact both companies. Lotte Biologics' reputation as a CDMO will be enhanced, potentially attracting more clients, while Ottimo Pharma's OTP-01 will accelerate its path to commercialization, which could lead to future revenue streams.

Biotechnology Pharmaceuticals
Event Summary

Lotte Biologics and Ottimo Pharma have expanded their strategic partnership, building on a previous antibody development and manufacturing agreement. This expanded collaboration will see Lotte Biologics' Syracuse Bio Campus team support commercial process development and characterization activities for Ottimo Pharma's biparatopic antibody, OTP-01, aiming for launch readiness. Both companies expressed confidence in the partnership, highlighting Lotte Biologics' quality and execution, and Ottimo Pharma's commitment to advancing its pipeline. The agreement reinforces Lotte Biologics' role as a pure-play CDMO with a dual-site strategy in the United States and South Korea, providing integrated services from clinical development through commercialization.

Entities Involved
priv
Lotte Biologics
Lotte Biologics has expanded its collaboration with Ottimo Pharma, reinforcing its role as a CDMO and its commitment to supporting clients from clinical development through commercialization. This partnership enhances its reputation and demonstrates its operational excellence.
Importance 100.0 Sentiment 70.0
priv
Ottimo Pharma
Ottimo Pharma has expanded its antibody manufacturing agreement with Lotte Biologics, demonstrating confidence in Lotte Biologics' capabilities. This collaboration will advance its biparatopic antibody, OTP-01, toward launch readiness, accelerating its development.
Importance 100.0 Sentiment 70.0
oth
OTP-01
OTP-01 is Ottimo Pharma's promising biparatopic antibody, which will be advanced toward launch readiness through the expanded collaboration with Lotte Biologics.
Importance 80.0 Sentiment 60.0
per
James Park (businessman)
As Co-CEO of Lotte Biologics, James Park announced the expanded collaboration, emphasizing the company's commitment to client support and molecule advancement.
Importance 70.0 Sentiment 60.0
per
Spencer Fisk
As Chief Technical and Quality Officer of Ottimo Pharma, Spencer Fisk expressed satisfaction with Lotte Biologics' partnership, quality, and speed, highlighting the importance of this expanded relationship for OTP-01's development.
Importance 70.0 Sentiment 60.0
per
Yooyeol Shin
As Co-CEO of Lotte Biologics, Yooyeol Shin is involved in the company's strategic decisions, including the expansion of this key partnership.
Importance 50.0 Sentiment 60.0
cnt
United States
Importance 0.0 Sentiment 0.0
cnt
South Korea
Importance 0.0 Sentiment 0.0
Relationships
United States related ↔ South Korea
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.